Wednesday, May 9, 2018
REGISTRATION & CONTINENTAL BREAKFAST
7:00 - 8:00  
WELCOME
8:00 - 8:15

Welcome and Introduction to the Programme

Harley Eisman, MD, Co-Founder, Hereditary Breast and Ovarian Cancer Foundation, Montréal, QC, Canada


William Foulkes, MBBS, PhD, Director, Program in Cancer Genetics, McGill University, Montréal, QC, Canada


Overview of Today’s Sessions

William Foulkes, MBBS, PhD, Director, Program in Cancer Genetics, McGill University, Montréal, QC, Canada

SESSION 1:
BRCA biology and gene variants
8:15 - 9:45

CHAIR: Lawrence Brody, PhD, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA

8:15 - 8:35

BIC, ENIGMA, BRCA Exchange and ClinVar: Where are we with data integration?

Amanda Spurdle, PhD, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia

8:35 - 8:55

BRCA1/2 VUS: What’s new in variant classification?

Alvaro Monteiro, PhD, Moffitt Cancer Center, Tampa, FL, USA

8:55 - 9:05

Proffered paper 1
An international interlaboratory study of complex pathogenic variants in hereditary breast/ovarian cancer

Stephen Lincoln, InVitae, San Francisco, CA, USA

9:05 - 9:15

Proffered paper 2
Pheno analysis is a highly accurate and robust variant classification algorithm with high tolerance for reported clinical history errors

Karla Bowles, PhD, FACMG, Myriad Genetic Laboratories, Salt Lake City, UT, USA

9:15 - 9:25

Proffered paper 3
Functional assays identify clinically actionable variants in hereditary breast and ovarian cancer predisposition genes

Rachid Karam, MD, PhD, Ambry Genetics, Aliso Viejo, CA, USA

9:25 - 9:45

Question and discussion period (all speakers)

BREAK
9:45 - 10:15  
SESSION 2:
Molecular genetics and pathology of inherited forms of breast and gynecological cancers
10:15 - 11:45

CHAIR: Jorge Reis-Filho, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

10:15 - 10:35

Breast cancer pathology, treatment and outcome in ATM, BRCA1, BRCA2, CHEK2 and PALB2 mutation carriers

Marjanka Schmidt, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands

10:35 - 10:55

Classifying ovarian cancers using molecular genetics and histology

Blaise Clarke, MD, University Health Network, Toronto, ON, Canada

10:55 - 11:05

Proffered paper 1
BRCA2 haploinsufficiency for replication stress suppression in primary BRCA2 heterozygous mammary epithelial cells

Shailja Pathania, PhD, University of Massachusetts Boston, Boston, MA, USA

11:05 - 11:15

Proffered paper 2
Aneuploidy and altered cell fate define the early pathogenesis of BRCA2-associated breast cancer

Leif Ellisen, MD, PhD, Massachsusetts General Hospital Cancer Center, Boston, MA, USA

11:15 - 11:25

Proffered paper 3
Functional analysis of the PALB2 tumor suppressor

Jean-Yves Masson, PhD, Laval University Cancer Research Center, Québec, QC, Canada

11:25 - 11:45

Question and discussion period (all speakers)

LUNCH

11:45 - 13:15  

SESSION 3:
DNA Repair in the clinic: origins, diagnosis and outcomes
13:15 - 14:45

CHAIR: Laura van’t Veer, PhD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA

13:15 - 13:35

Genomic Consequences of Aberrant DNA repair in Breast and Ovarian cancer – implications for therapy

Alan D. D'Andrea, M.D., Director: Susan F. Smith Center for Women's Cancers (SFSCWC), The Fuller-American Cancer Society Professor, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA

13:35 - 13:55

DNA Repair in Clinical Practice

Daniel Silver, MD, PhD, Thomas Jefferson University, Philadelphia, PA, USA

14:05 - 14:15

Proffered paper 1
Modulation of base excision repair influences DNA damage repair for BRCA2 mutant cancer: Implications for chemotherapeutics

Shailja Pathania, PhD, University of Massachusetts Boston, Boston, MA, USA

14:15 - 14:25

Proffered paper 2
Impact of DNA repair defects on the outcomes of metastatic resistant prostate cancer (mCRPC)

Elena Castro, MD, PhD, Spanish National Cancer Research Centre, Madrid, Spain

14:25 - 14:45

Question and discussion period (all speakers)

POSTER SESSION 1
    (with break)
14:45 - 16:30
SESSION 4:
Special Round Table: BRCA1/2 clinical practice – global perspectives
16:30 - 18:00

MODERATORS: Mark Robson, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; and Lawrence Brody, PhD, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA

South America:

Maria Isabel Achatz, MD, PhD, Hospital Sírio e Libanês, Brazil, and National Cancer Institute, USA

Europe:

Dominique Stoppa-Lyonnet, PhD, Institut Curie, Paris, France

African Perspective:

Prisca Olabisi Adejumo, PhD, University of Ibadan, Ibadan, Nigeria

Asian Perspective:

Mercy Laurino, MS, LCGC, PhD, University of the Philippines Manila - Philippine General Hospital Manila, Philippines, and Cancer Prevention Programs, Seattle Cancer Care Alliance